FDBusiness.com

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

 Breaking News
  • Tectonic-sized Shift in Consumer Shopping Behaviour Following Coronavirus Pandemic Spread the loveE.fundamentals, an industry-leading digital shelf analytics provider, has revealed the results of a comprehensive and exclusive new survey in partnership with YouGov. Commissioned to uncover how the coronavirus...
  • Recognising the Best in the Industry Spread the loveOnce again this year, during Fi Europe co-located with Hi Europe at the beginning of December, show organizer Informa Markets will be recognizing companies and organizations for groundbreaking novelties...
  • Burts Snacks Announces New Managing Director Spread the loveBurts Snacks, one of the UK’s leading independent snacking companies, has announced that its chairman and managing director, David Nairn is stepping down after 14 years leading the...
  • Kerry Group Shows Resilience Spread the loveKerry Group, the global taste & nutrition and consumer foods business, has reported a 4.3% decrease in revenue to €3.4 billion for the first half ended 30 June...
  • A Year of Two Halves For Diageo Spread the loveDiageo has reported an 8.7% decline in net sales to £11.8 billion and a 47.1% decrease in operating profit to £2.1 billion for the year ended June 2020...

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients
September 11
09:01 2012
Spread the love

Biotech company Enzymotec has reported that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results. This plan is part of a comprehensive business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA).Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months. These large-scale clinical research trials were conducted on newborn term infants in several institutes worldwide. Clinical results already have been presented at leading professional conferences.

One of the studies recently completed was a controlled clinical trial on InFat®. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. It enables easy digestion and optimized uptake of calcium, fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture between AAK and Enzymotec. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being. It was conducted by Professor Chen Yu-Ming, the principle investigator at SunYat-Sen Universityand in collaboration with Enzymotec.

“The clinical trials plan represents Enzymotec’s ongoing commitment to explore the special characteristics of human milk and demonstrate its lipid-based ingredients’ health benefits on various infant populations,” says Yael Lifshitz, PhD, Director of R&D, of Enzymotec Infant Nutrition. “We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development—a percentage considered among the highest in the industry.”


Warning: count(): Parameter must be an array or an object that implements Countable in /home/fdbusiness/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5

About Author

mike

mike

Related Articles

Food & Drink Business Conference & Exhibition 2016

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here



Advertisements